サンプル依頼リスト カート
  • English
  • Korean
表紙：神経障害性疼痛の世界市場レポート 2024年
市場調査レポート
商品コード
1415669

神経障害性疼痛の世界市場レポート 2024年

Neuropathic Pain Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
神経障害性疼痛の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

神経障害性疼痛の市場規模は近年力強く成長しています。2023年の49億5,000万米ドルから2024年には53億5,000万米ドルに、CAGR8.3％で拡大します。歴史的な期間の成長は、神経障害性疼痛医薬品に対する需要の増加、慢性疼痛の流行、処方箋治療に対する需要の増加、政府の取り組みに起因しています。

神経障害性疼痛市場規模は、今後数年間で力強い成長が見込まれます。2028年には71億6,000万米ドルに成長し、CAGRは7.5％となります。予測期間の成長は、神経障害性疼痛の認知度向上、高齢化、ヘルスケア分野の充実、神経障害性疼痛治療へのアクセスのしやすさなどに起因しています。予測期間の主な動向としては、診断法の改善、疼痛管理の進歩、医学研究の進歩、新薬承認、戦略的イニシアティブなどが挙げられます。

慢性疼痛の有病率の上昇は、今後の神経障害性疼痛市場成長の重要な促進要因になると予測されます。慢性疼痛は、怪我や病気の治癒期間を超えて持続するのが特徴で、その期間は通常3～6ヵ月以上に及ぶ。神経障害性疾患を含む慢性疼痛の増加は、効果的な治療法の必要性を強調しています。そのため、症状の緩和と全体的な生活の質の向上を目指した、より良い治療法の開発に対する研究、技術革新、投資が活発化しています。例えば、2023年4月現在、米国の国立公衆衛生機関である疾病対策予防センターがMorbidity and Mortality Weekly Report（MMWR）に発表したデータによると、2021年には米国の成人約5,160万人（20.9％）が慢性疼痛と闘い、1,710万人（6.9％）が影響の大きい慢性疼痛を経験していることが明らかになった。米国生まれ（21.6％）の慢性疼痛の有病率は、米国外生まれ（11.9％）の約2倍であったことは注目に値します。同様に、高負荷の慢性疼痛の有病率は、米国外出身者（4.1％）に比べ、米国出身者（7.0％）で高かったです。したがって、慢性疼痛の急増が神経障害性疼痛市場成長の原動力となっています。

糖尿病有病率の増加が、神経障害性疼痛市場成長の原動力になると予想されます。糖尿病は、血液中のグルコース（糖）レベルの上昇を特徴とする慢性的な病状であり、糖尿病の最も一般的な慢性合併症の一つである神経障害の重大な原因となっています。神経障害の中でも、糖尿病性末梢神経障害（DPN）は最も一般的であり、最も広範に研究されている治療法です。例えば、米国に本部を置く非営利団体である国際糖尿病連合（International Diabetes Federation）による糖尿病アトラス（Diabetes Atlas）で報告されているように、糖尿病を患っている20～79歳の成人の世界人口は、2021年には約5億3,700万人となった。さらに、糖尿病の罹患者数は2030年までに6億4,300万人に増加し、2045年には7億8,300万人に達すると予測されています。その結果、神経障害性疼痛市場の成長は、糖尿病患者数の増加と密接に関連しています。

2023年の神経障害性疼痛市場では北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域と予想されます。神経障害性疼痛レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東およびアフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の神経障害性疼痛市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 薬剤
  • 集学的治療
  • 世界の神経障害性疼痛市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • イメージング
  • 血液検査と身体検査
  • 世界の神経障害性疼痛市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 糖尿病性神経障害
  • 脊柱管狭窄症
  • 化学療法誘発性末梢神経障害
  • その他
  • 世界の神経障害性疼痛市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • クリニック
  • 在宅ヘルスケア
  • 外来手術センター
  • その他

第7章 地域および国の分析

  • 世界の神経障害性疼痛市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の神経障害性疼痛市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経障害性疼痛市場の競合情勢
  • 神経障害性疼痛市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Private Limited
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • Abbott Laboratories

第31章 その他の主要および革新的な企業

  • GlaxoSmithKline Plc
  • Medtronic Inc.
  • Eli Lilly and Company
  • Stryker Corporation
  • Baxter International Inc.
  • Teva Pharmaceutical Industries Ltd
  • Boston Scientific Corporation
  • Biogen Inc.
  • Zimmer Biomet Holdings Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Grunenthal GmbH
  • Lupin Ltd.
  • NuVasive Inc.
  • Integer Holdings Corporation

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12268

“Neuropathic Pain Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuropathic pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuropathic pain? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The neuropathic pain market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment: Medications; Multimodal Therapy
  • 2) By Diagnosis: Imaging; Blood Tests And Physical Examination
  • 3) By Indication: Diabetic Neuropathy; Spinal Stenosis; Chemotherapy-Induced Peripheral Neuropathy; Other Indications
  • 4) By End User: Hospitals; Clinics; Home Healthcare; Ambulatory Surgical Centers; Other End Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Sanofi S.A.; Bristol-Myers Squibb Company; Abbott Laboratories
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Neuropathic pain, a persistent condition resulting from nervous system damage or dysfunction, is characterized by sensations like burning, tingling, shooting, or electric shocks. Treating neuropathic pain can be complex, with causes including nerve injuries, diabetes, multiple sclerosis, nerve compression, neural degeneration, and central nervous system disorders.

The primary approaches to neuropathic pain treatment include medications and multimodal therapy. Medications involve the use of pharmaceutical substances to alleviate symptoms and manage conditions. Certain drugs, such as anticonvulsants, antidepressants, and opioids, are effective in targeting nerve-related abnormalities and pathways. They work to reduce the intensity of neuropathic pain signals, offering relief. Neuropathic pain diagnosis typically involves imaging, blood tests, and physical examinations. These diagnostic procedures are relevant for conditions like diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others. They are commonly administered in healthcare settings such as hospitals, clinics, home healthcare, and ambulatory surgical centers.

The neuropathic pain market research report is one of a series of new reports from The Business Research Company that provides neuropathic pain market statistics, including neuropathic pain industry global market size, regional shares, competitors with a neuropathic pain market share, detailed neuropathic pain market segments, market trends and opportunities and any further data you may need to thrive in the neuropathic pain industry. This neuropathic pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuropathic pain market size has grown strongly in recent years. It will grow from $4.95 billion in 2023 to $5.35 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing demand for neuropathic pain drugs, chronic pain epidemic, growing demand for prescription treatments, government initiatives.

The neuropathic pain market size is expected to see strong growth in the next few years. It will grow to $7.16 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing awareness of neuropathic pain, aging population, well-proliferated healthcare sector, accessibility to neuropathic pain treatments. Major trends in the forecast period include improved diagnostics, advancements in pain management, advancements in medical research, new drug approvals, strategic initiatives.

The rising prevalence of chronic pain is anticipated to be a significant driver for the growth of the neuropathic pain market in the future. Chronic pain is characterized by its persistency, lasting beyond the expected healing period following an injury or illness, typically spanning a duration of three to six months or more. The increasing occurrence of chronic pain, including neuropathic conditions, underscores the need for effective treatments. This, in turn, stimulates research, innovation, and investment in the development of improved therapies aimed at enhancing symptom relief and overall quality of life. For instance, as of April 2023, data published in the Morbidity and Mortality Weekly Report (MMWR) by the Centers for Disease Control and Prevention, a national public health agency in the United States, revealed that in 2021, approximately 51.6 million U.S. adults (20.9%) grappled with chronic pain, with 17.1 million (6.9%) experiencing high-impact chronic pain. It is noteworthy that the prevalence of chronic pain among individuals born in the U.S. (21.6%) was nearly twice that of those born outside the U.S. (11.9%). Likewise, high-impact chronic pain was more prevalent among U.S.-born individuals (7.0%) compared to those born outside the U.S. (4.1%). Hence, the burgeoning incidence of chronic pain is a driving force behind the prospective growth of the neuropathic pain market.

The expected increase in the prevalence of diabetes is set to be a driving force behind the future growth of the neuropathic pain market. Diabetes, a chronic medical condition characterized by elevated levels of glucose (sugar) in the bloodstream, is a significant contributor to neuropathies, which are among the most common chronic complications of diabetes, affecting more than 50% of individuals with diabetes over their lifetime. Among neuropathy types, diabetic peripheral neuropathy (DPN) is the most prevalent and is associated with the most extensively researched treatment methods. For instance, as reported in the Diabetes Atlas by the International Diabetes Federation, a non-profit organization based in the United States, the global population of adults aged 20 to 79 living with diabetes stood at approximately 537 million in 2021. Furthermore, the overall count of individuals affected by diabetes is projected to increase to 643 million by 2030 and reach 783 million by 2045. Consequently, the growth of the neuropathic pain market is closely linked to the escalating number of diabetes cases.

The substantial costs associated with medications pose a notable obstacle that impedes the expansion of the neuropathic pain market. These costs limit patient access to essential treatments and create financial barriers that can deter both patients and healthcare providers from pursuing comprehensive pain management strategies. For example, as indicated in a study published in October 2022 at the National Library of Medicine, a U.S.-based medical library, there remains a significant unmet need in the pharmacological treatment of neuropathic pain, with many patients experiencing an inadequate response. The study also underscores that neuropathic pain affects 7-10% of the population, and the majority of these patients receive treatments that are insufficient and incomplete. Therefore, the high cost of neuropathic pain treatment acts as a deterrent, hampering the growth of the market.

The leading companies in the neuropathic pain market are embracing artificial intelligence technologies to revolutionize various facets of pain management. These innovations encompass advanced diagnosis, tailored treatment plans, real-time monitoring, drug discovery, and data-driven insights, all aimed at optimizing patient outcomes and refining pain management strategies. For instance, in March 2023, Nevro Corp., a U.S.-based medical device company, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This cutting-edge technology harnesses the power of artificial intelligence (AI) to deliver customized pain relief solutions for individual patients. The system, which comprises the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is designed to address non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. Utilizing a unique algorithm informed by extensive patient data, the system allows patients to fine-tune their pain relief programs through a smartphone app. The digital ecosystem of the system enables continuous data collection and potential updates. The primary goal of this technology is to elevate pain relief by offering consistency and personalization, representing a significant advancement in SCS therapy.

In March 2021, Horizon Therapeutics PLC, an Irish biotechnology company, completed its acquisition of Viela Bio, Inc., for a sum of $3.1 billion. This strategic acquisition bolstered Horizon Therapeutics' presence in the realm of autoimmune and severe inflammatory diseases by incorporating UPLIZNA, the first and only B-cell-depleting humanized monoclonal antibody approved by the U.S. Food and Drug Administration for treating neuromyelitis optica spectrum disorder (NMOSD). Viela Bio, Inc., is a U.S.-based biotechnology company specializing in the development of treatments for neuropathic pain resulting from autoimmune or inflammatory conditions.

Major players in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic Inc., Eli Lilly and Company, Stryker Corporation, Baxter International Inc., Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Biogen Inc., Zimmer Biomet Holdings Inc. , Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grunenthal GmbH, Lupin Ltd., NuVasive Inc., Integer Holdings Corporation, Avanos Medical Inc., Orthofix Medical Inc., Nevro Corp., InvaGen Pharmaceuticals Inc, B. Braun Melsungen AG, Cirtec Medical Corp., Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, DePuy Synthes .

North America was the largest region in the neuropathic pain market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuropathic pain report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuropathic pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuropathic pain market consists of revenues earned by entities by providing physical therapy services, acupuncture services and relaxation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuropathic pain market also includes sales of anticonvulsants, antidepressants, opioids, topical creams and transcutaneous electrical nerve stimulation devices, which are used in providing neuropathic pain diagnosis and treatment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Neuropathic Pain Market Characteristics

3. Neuropathic Pain Market Trends And Strategies

4. Neuropathic Pain Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Neuropathic Pain Market Size and Growth

  • 5.1. Global Neuropathic Pain Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Neuropathic Pain Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Neuropathic Pain Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neuropathic Pain Market Segmentation

  • 6.1. Global Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medications
  • Multimodal Therapy
  • 6.2. Global Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Imaging
  • Blood Tests And Physical Examination
  • 6.3. Global Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diabetic Neuropathy
  • Spinal Stenosis
  • Chemotherapy-Induced Peripheral Neuropathy
  • Other Indications
  • 6.4. Global Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Home Healthcare
  • Ambulatory Surgical Centers
  • Other End Users

7. Neuropathic Pain Market Regional And Country Analysis

  • 7.1. Global Neuropathic Pain Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Neuropathic Pain Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neuropathic Pain Market

  • 8.1. Asia-Pacific Neuropathic Pain Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neuropathic Pain Market

  • 9.1. China Neuropathic Pain Market Overview
  • 9.2. China Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neuropathic Pain Market

  • 10.1. India Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neuropathic Pain Market

  • 11.1. Japan Neuropathic Pain Market Overview
  • 11.2. Japan Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neuropathic Pain Market

  • 12.1. Australia Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neuropathic Pain Market

  • 13.1. Indonesia Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neuropathic Pain Market

  • 14.1. South Korea Neuropathic Pain Market Overview
  • 14.2. South Korea Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neuropathic Pain Market

  • 15.1. Western Europe Neuropathic Pain Market Overview
  • 15.2. Western Europe Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neuropathic Pain Market

  • 16.1. UK Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neuropathic Pain Market

  • 17.1. Germany Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neuropathic Pain Market

  • 18.1. France Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neuropathic Pain Market

  • 19.1. Italy Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neuropathic Pain Market

  • 20.1. Spain Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neuropathic Pain Market

  • 21.1. Eastern Europe Neuropathic Pain Market Overview
  • 21.2. Eastern Europe Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neuropathic Pain Market

  • 22.1. Russia Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neuropathic Pain Market

  • 23.1. North America Neuropathic Pain Market Overview
  • 23.2. North America Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neuropathic Pain Market

  • 24.1. USA Neuropathic Pain Market Overview
  • 24.2. USA Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neuropathic Pain Market

  • 25.1. Canada Neuropathic Pain Market Overview
  • 25.2. Canada Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neuropathic Pain Market

  • 26.1. South America Neuropathic Pain Market Overview
  • 26.2. South America Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neuropathic Pain Market

  • 27.1. Brazil Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neuropathic Pain Market

  • 28.1. Middle East Neuropathic Pain Market Overview
  • 28.2. Middle East Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neuropathic Pain Market

  • 29.1. Africa Neuropathic Pain Market Overview
  • 29.2. Africa Neuropathic Pain Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neuropathic Pain Market Competitive Landscape And Company Profiles

  • 30.1. Neuropathic Pain Market Competitive Landscape
  • 30.2. Neuropathic Pain Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Private Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sanofi S.A.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bristol-Myers Squibb Company
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Abbott Laboratories
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Neuropathic Pain Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline Plc
  • 31.2. Medtronic Inc.
  • 31.3. Eli Lilly and Company
  • 31.4. Stryker Corporation
  • 31.5. Baxter International Inc.
  • 31.6. Teva Pharmaceutical Industries Ltd
  • 31.7. Boston Scientific Corporation
  • 31.8. Biogen Inc.
  • 31.9. Zimmer Biomet Holdings Inc.
  • 31.10. Sun Pharmaceutical Industries Ltd.
  • 31.11. Mallinckrodt Pharmaceuticals
  • 31.12. Grunenthal GmbH
  • 31.13. Lupin Ltd.
  • 31.14. NuVasive Inc.
  • 31.15. Integer Holdings Corporation

32. Global Neuropathic Pain Market Competitive Benchmarking

33. Global Neuropathic Pain Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neuropathic Pain Market

35. Neuropathic Pain Market Future Outlook and Potential Analysis

  • 35.1 Neuropathic Pain Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Neuropathic Pain Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Neuropathic Pain Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer